299 related articles for article (PubMed ID: 3530444)
1. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study.
Andersson M; Daugaard S; von der Maase H; Mouridsen HT
Cancer Treat Rep; 1986 Oct; 70(10):1181-6. PubMed ID: 3530444
[TBL] [Abstract][Full Text] [Related]
2. Mitomycin C, methotrexate, and vincristine with medroxyprogesterone acetate or prednisolone for doxorubicin resistant advanced breast cancer--a randomized control study.
Tashiro H; Nomura Y
Anticancer Res; 1995; 15(5B):2229-37. PubMed ID: 8572630
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
[TBL] [Abstract][Full Text] [Related]
6. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.
Dieras V; Marty M; Tubiana N; Corette L; Morvan F; Serin D; Mignot L; Chazard M; Garet F; Onetto N
Semin Oncol; 1995 Aug; 22(4 Suppl 8):33-9. PubMed ID: 7638640
[TBL] [Abstract][Full Text] [Related]
7. Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer.
Bishop JF; Raghavan D; Woods R; Coates A; Burns I; Jeal PN; Hillcoat BL; Tattersall MN
Cancer Treat Rep; 1987 Feb; 71(2):191-3. PubMed ID: 2433037
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
9. [Combination chemotherapy of 5-fluorouracil (5-FU), adriamycin (ADM), cis-diamminedichloroplatinum (II) (CDDP) and mitomycin C (MMC) (FAP.MMC) in advanced gastric cancer].
Ozeki H; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Ito Y; Imajo K; Shinagawa K
Gan To Kagaku Ryoho; 1988 Jan; 15(1):91-5. PubMed ID: 3122669
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer.
Ford JM; Panasci L; Leclerc Y; Margolese R
Cancer Treat Rep; 1987 Oct; 71(10):921-5. PubMed ID: 3308079
[TBL] [Abstract][Full Text] [Related]
11. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
[TBL] [Abstract][Full Text] [Related]
12. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19.
Liu J; Tu D; Dancey J; Reyno L; Pritchard KI; Pater J; Seymour LK
Breast Cancer Res Treat; 2006 Dec; 100(3):263-71. PubMed ID: 16823511
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
Sledge GW; Robert N; Sparano JA; Cobeligh M; Goldstein LJ; Neuberg D; Rowinsky E; Baughman C; McCaskill-Stevens W
Semin Oncol; 1994 Oct; 21(5 Suppl 8):15-8. PubMed ID: 7939756
[TBL] [Abstract][Full Text] [Related]
14. Mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer.
Falkson G; Gelman RS; Tormey DC; Taylor SG; Falkson HC
Cancer Treat Rep; 1985; 69(7-8):755-60. PubMed ID: 4016786
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic effect of stage III breast cancer--comparative study of preoperative intra-arterial infusion chemotherapy and non-infusion therapy].
Masuoka H; Asaishi K; Toda K; Okazaki M; Okazaki Y; Hayasaka H; Miyake H; Mori M
Gan To Kagaku Ryoho; 1989 May; 16(5):2067-73. PubMed ID: 2543329
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide.
Joss RA; Alberto P; Obrecht JP; Barrelet L; Holdener EE; Siegenthaler P; Goldhirsch A; Mermillod B; Cavalli F
Cancer Treat Rep; 1984 Sep; 68(9):1079-84. PubMed ID: 6090014
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
[TBL] [Abstract][Full Text] [Related]
19. Adriamycin and mitomycin C: possible synergistic cardiotoxicity.
Buzdar AU; Legha SS; Tashima CK; Hortobagyi GN; Yap HY; Krutchik AN; Luna MA; Blumenschein GR
Cancer Treat Rep; 1978 Jul; 62(7):1005-8. PubMed ID: 688243
[TBL] [Abstract][Full Text] [Related]
20. Melphalan with and without doxorubicin in advanced ovarian cancer.
Tropé C
Obstet Gynecol; 1987 Oct; 70(4):582-6. PubMed ID: 3306509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
